建中强心汤联合曲美他嗪对慢性心力衰竭患者的疗效和预后的影响

Effect and prognosis of Jianzhong Qiangxin Decoction combined with Trimetazidine in patients with chronic heart failure

目的探讨建中强心汤联合曲美他嗪对慢性心力衰竭(CHF)患者的疗效和预后影响。方法选取2021年6月至2022年6月鹤山市中医院收治的128例CHF患者作为研究对象,按照随机数字表法分为对照组与观察组,每组64例。对照组采用曲美他嗪治疗,观察组采用建中强心汤联合曲美他嗪治疗。比较两组患者疗效、心功能、6 min步行距离、中医证候积分、不良反应发生率和累积再入院率。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者左室收缩末期内径(LVESD)和左室舒张末期内径(LVEDD)低于本组治疗前,左心室射血分数(LVEF)高于本组治疗前,且观察组LVESD和LVEDD低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。观察组治疗后6 min步行距离高于对照组,中医证候积分低于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者生活质量评分高于本组治疗前,且观察组生活质量评分高于对照组,差异有统计学意义(P<0.05)。观察组治疗后累计再入院率低于对照组,差异有统计学意义(χ^(2)=5.851,P=0.016)。结论CHF患者采用建中强心汤联合曲美他嗪治疗,临床效果显著,且可有效改善患者心功能,提升患者预后生活质量,降低再入院发生率,值得在临床推广应用。

Objective To investigate the effect and prognosis of Jianzhong Qiangxin Decoction combined with Trimetazidine in patients with chronic heart failure(CHF).Methods A total of 128 CHF patients admitted to Heshan Hospital of Chinese Medicine from June 2021 to June 2022 were selected as research objects,and they were divided into control group and observation group according to random number table method,with 64 cases in each group.The control group was treated with Trimetazidine,and the observation group was treated with Jianzhong Qiangxin Decoction combined with Trimetazidine.The efficacy,heart function,6-min walking distance,traditional Chinese medicine syndrome score,incidence of adverse reactions and cumulative readmission rate were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)in two groups were lower than those before treatment,left ventricular ejection fraction(LVEF)were higher than those before treatment,and LVESD and LVEDD in observation group were lower than those of control group,LVEF was higher than that of control group,with statistical significances(P<0.05).The 6-min walking distance after treatment in the observation group was higher than that in the control group,and the traditional Chinese medicine syndrome score was lower than that in the control group,the differences were statistically significant(P<0.05).After treatment,the quality of life scores of two groups were higher than those before treatment,and the quality of life score of observation group was higher than that of control group,the differences were statistically significant(P<0.05).The cumulative readmission rate of the observation group was lower than that of the control group,and the difference was statistically significant(χ^(2)=5.851,P=0.016).Conclusion Jianzhong Qiangxin Decoction combined with Trimetazidine has significant clinical effect in CHF patients,and can effectively improve the cardiac function,prognosis and quality of life of patients,and reduce the incidence of readmission,which is worthy of clinical promotion and application.